Zinger Key Points
- Q1 adjusted EPS: $5.15 vs. $5.10 estimate; revenue: $10.36 billion vs. $10.23 billion expected.
- Life Sciences revenue rose 2.5%, Specialty Diagnostics up 3.5%, Biopharma fell 1.5%.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Thermo Fisher Scientific Inc. TMO reported first-quarter 2025 adjusted earnings per share of $5.15 on Wednesday, beating the street view of $5.10.
Quarterly sales of $10.36 billion, almost flat year over year, outpaced the analyst consensus estimate of $10.23 billion. Organic revenue growth was 1%.
“We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I’m incredibly proud of our team’s execution,” said Marc Casper, chairman, president, and CEO of Thermo Fisher Scientific. “Our team leveraged the PPI Business System to drive operational excellence and enable our customers’ success.”
Casper added: “Thermo Fisher is incredibly well-positioned. Our experienced management team has a proven track record, and as the trusted partner to our customers, we will help them manage the current environment, identifying new opportunities and ultimately creating value for all our stakeholders.”
Also Read: 3M Spin-Off Solventum Targets Higher Margins, EPS Growth In 2025-2028 Strategy
Thermo Fisher’s adjusted operating income for the first quarter of 2025 was $2.27 billion, compared with $2.28 billion in the year-ago quarter.
- Adjusted operating margin was 21.9%, compared with 22% in the first quarter of 2024.
Revenue from the Life Sciences Solutions Segment increased by 2.5% year over year to $2.34 billion. Analytical Instruments Segment sales were up 1.8% to $1.72 billion.
Specialty Diagnostics Segment revenues increased 3.5% to $1.15 billion, and Laboratory Products and Biopharma Services segment sales were down 1.5% at $5.64 billion.
Thermo Fisher Scientific agreed to acquire Solventum’s SOLV Purification & Filtration business in February for approximately $4.1 billion in cash.
Solventum's Purification & Filtration business provides purification and filtration technologies for the production of biologics, medical technologies, and industrial applications.
Price Action: Thermo Fisher stock is trading 4.23% higher at $453.10 at the last check Wednesday.
Read Next:
Image: Shutterstock
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.